Trial Identifier: | 015K-CL-CNA3 |
Sponsor: | Astellas Pharma China, Inc. |
Start Date: | September 2018 |
Primary Completion Date: | April 2021 |
Study Completion Date: | November 2021 |
Condition: | Rheumatoid Arthritis |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
Language | Description |
Country | Location |
---|---|
China | Anhui, China |
China | Beijing, China |
China | Bengbu, China |
China | Changchun, China |
China | Changsha, China |
China | Chenzhou, China |
China | Guangdong, China |
China | Guangzhou, China |
China | Inner Mongolia, China |
China | Jieyang, China |
China | Jilin, China |
China | Jining, China |
China | Jiujiang, China |
China | Kunming, China |
China | Nanjing, China |
China | Ningbo, China |
China | Pingxiang, China |
China | Qingdao, China |
China | Shanghai, China |
China | Shantou, China |
China | Sichuan, China |
China | Tianjin, China |
China | Wuhan, China |
China | Xining, China |
China | Xuzhou, China |
China | Zhengzhou, China |
China | Zhuzhou, China |
Korea (Republic of) | Gwangju, Korea (Republic of) |
Korea (Republic of) | Incheon, Korea (Republic of) |
Korea (Republic of) | Seoul, Korea (Republic of) |
Taiwan, Province of China | Taichung, Taiwan, Province of China |
Taiwan, Province of China | Taipei, Taiwan, Province of China |